Literature DB >> 12423515

Inactivation of HIV in blood.

Asa Ohagen1, Veronica Gibaja, Saika Aytay, Jeff Horrigan, Douglas Lunderville, Aris Lazo.   

Abstract

BACKGROUND: The residual risk of HIV infection after HIV screening tests in combination with the risk of new emerging pathogens entering the blood supply has sparked research on the development of a technology for reduction of pathogens in RBCs. STUDY DESIGN AND METHODS: HIV-1 was treated with PEN110 (INACTINE) and analyzed for the kinetics of virus reduction in RBC, the effect of PEN110 on nucleic acids, the integrity of the virus morphology and viral proteins, and the ability of the virus to bind HIV cell receptors and enter susceptible cells.
RESULTS: PEN110 effectively reduced HIV-1 to the limit of detection for a reduction factor of at least 5.57 log 50 percent tissue culture infectious dose per bulk test. The PEN110-treated virions maintained their morphology, protein integrity, and functionality. However, the PEN110-treated HIV-1 RNA genome was neither functional to serve as a template for RT-PCR amplification of about 1 kb nor able to support viral DNA synthesis in cell culture.
CONCLUSION: These results suggest that PEN110 inactivates HIV-1 by targeting the viral nucleic acid.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423515     DOI: 10.1046/j.1537-2995.2002.00217.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters.

Authors:  Gadi Borkow; Humberto H Lara; Chandice Y Covington; Adeline Nyamathi; Jeffrey Gabbay
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 2.  Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.

Authors:  Jean Pierre Allain; Celso Bianco; Morris A Blajchman; Mark E Brecher; Michael Busch; David Leiby; Lily Lin; Susan Stramer
Journal:  Transfus Med Rev       Date:  2005-04

Review 3.  Pathogen inactivation techniques.

Authors:  J P R Pelletier; S Transue; E L Snyder
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.